Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

WuXi AppTec Completes First Phase of $125 Million Biologics Manufacturing Facility

publication date: Sep 22, 2016
WuXi Biologics, a division of WuXi AppTec, a China CRO/CMO, has completed construction of the first phase of a commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China. The entire project, announced in 2015, is expected to cost $150 million. The first phase includes two 1000L disposable bioreactors for perfusion processes. WuXi says the plant is the largest perfusion biologics manufacturing facility currently operating in Asia that uses disposable bioreactors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020